We have commented previously that the impact of technology and innovation often has unintended consequences. Often these consequences can result in entire paradigm shifts. Shifts that can disrupt and potentially wreck well etsablished exiting business models. Indeed histroy is littered with companies that simply “didn’t see it coming”.
The iphone is having such an impact. Not just in the consumer area, [...]

[Read more →]

“A Dutch research centre has developed a wireless monitor that allows your organs to send alerts to your mobile phone.”

Good lord. Somewhere a medical device company who is in the process or who have already raised a fortune to pay for their proprietary diagnostic technology and device, have just has conniptions!
The ehealth revolution is [...]

[Read more →]

We love Apps.
One of the core reasons, and there are many, is that Apps are in essence single function solutions. An App focuses only on doing one job, or group of related jobs. Importantly, it does so in the most economical and simplest fashion. As a result , no over engineering, no complexity, no huge [...]

[Read more →]

I am not sure how aware you are of the increasing trend towards crowd sourced solutions. But if not, you probably should be.
The central tenet of the crowd sourced solution is that it provides you access to a wider range of solutions at a lower cost.
Crowd sourcing is an emerging model right across a range of areas. Initially, it [...]

[Read more →]

As you may be aware Cogentum’s client Acrux (ASX:ACR) yesterday announced that the FDA has approved its Axiron product for marketing in the US. The news received wide media coverage which is a great reflection of the importance of the news!
This announcement is a watershed moment for the Australian Biotech sector and marks a significant [...]

[Read more →]

Alzheimers is a very real and human tragedy that robs people not only of their the identify but also their sense of purpose and place in the world. Dealing with Alzheimers patients is even more difficult.
One of the recurring issues with Alzheimers patients is the development of episodes where the patient has a sudden and urgent need ‘to get home’. [...]

[Read more →]

Cogentum client Acrux today announced one of the biggest licensing  deals in Australian Biotech history. The deal with Eli Lilly ranks up there as one of the biggest outcomes for an Australian biotech. From the announcements you will see that this is a superb result for any Australian company seeking to license it’s technology.

Cogentum worked [...]

[Read more →]

The following piece appeared in September 28th edition of Bioshares #330, Australia’s leading analysis and commentary on the Biotech sector. It summarises our out take on the 2009 Bioshares conference held at Thredbo in September.

Don’t worry about your Technology, show me the Strategy

The 2009 Thredbo summit graphically illustrated why strategy is becoming increasingly more valuable [...]

[Read more →]

It would seem that the Australian Federal Government is still under intense pressure to follow the tired and hopeless old formula to solving the hospital bed crisis. The Australian Medical Association is pressuring the Government to “immediately spend at least $3 billion on 3,750 new public hospital beds and the staff and infrastructure to service [...]

[Read more →]

For some time we have heard media, political opposition parties and lobby and community groups complain about the hospital bed crisis.
Put simply, there are not enough Hospital beds for those patients who need them.
However,  the solution that is often put forward - building new hospitals, commissioning new wards, creating new beds is not the answer.
In [...]

[Read more →]